A phase II trial is recruiting MM patients with HR mutation or alteration who have had disease progression on previous immunotherapy, BRAF inhibitor, or both, to evaluate the efficacy and safety of monotherapy with niraparib (NCT03925350). Here, BRAF is linked to Miyoshi myopathy.